Brentuximab vedotin is an antibody-drug conjugate used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It consists of the monoclonal antibody cAC10 linked to the microtubule inhibitor MMAE. When the antibody binds to CD30 proteins on lymphoma cells, the complex is internalized and MMAE is released, disrupting the microtubule network and causing cell death. Brentuximab vedotin allows targeted delivery of the cytotoxic agent to minimize side effects compared to conventional chemotherapy. Common side effects include neuropathy, nausea, fatigue, and low blood cell counts.
CAR-T cells are T cells that are genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens on tumor cells. The first CAR-T cell therapy, Kymriah, was approved in 2017 for treating B-cell acute lymphoblastic leukemia. It showed high rates of complete remission. While effective, CAR-T cells can cause cytokine release syndrome and neurotoxicity as side effects. Ongoing research aims to expand CAR-T cell use in solid tumors and improve their safety profile.
Brentuximab vedotin is an antibody-drug conjugate used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma. It consists of the monoclonal antibody cAC10 linked to the microtubule inhibitor MMAE. When the antibody binds to CD30 proteins on lymphoma cells, the complex is internalized and MMAE is released, disrupting the microtubule network and causing cell death. Brentuximab vedotin allows targeted delivery of the cytotoxic agent to minimize side effects compared to conventional chemotherapy. Common side effects include neuropathy, nausea, fatigue, and low blood cell counts.
CAR-T cells are T cells that are genetically engineered to express chimeric antigen receptors (CARs) that target specific antigens on tumor cells. The first CAR-T cell therapy, Kymriah, was approved in 2017 for treating B-cell acute lymphoblastic leukemia. It showed high rates of complete remission. While effective, CAR-T cells can cause cytokine release syndrome and neurotoxicity as side effects. Ongoing research aims to expand CAR-T cell use in solid tumors and improve their safety profile.
Important Clinical Trials In Cardiology - An Overview 2016-17Amit Verma
A randomized clinical trial compared outcomes of 885 patients with STEMI and multivessel disease who underwent primary PCI of an infarct artery and were then randomly assigned to either complete revascularization of additional arteries guided by FFR (fractional flow reserve) or no further intervention. The primary composite outcome of death, MI, revascularization or stroke occurred in 8% of those who received complete revascularization versus 21% of those who received PCI only of the infarct artery. Complete revascularization significantly reduced risk of future cardiovascular events.
This PPT is about immune system and immune therapy, some basic knowledge about Chimeric Antigen Receptor or CAR technology and its application on tumor therapy.
Stem Cells in A New Era of Cell based Therapies - Creative BiolabsCreative-Biolabs
This document discusses stem cells and their applications in cell-based therapies. It defines stem cells as having endless self-renewal and the ability to differentiate into any cell type. Stem cells are classified by potency and origin, and can be embryonic, adult, or induced. The document outlines how different stem cell types like mesenchymal stem cells can treat diseases by regenerating tissues. Current stem cell therapy research aims to treat cancer, autoimmune diseases, and genetic disorders by using stem cells as drug delivery vehicles or for immunotherapy.
cardiac bio markers are important diagnostic and prognostic tool in acute coronary syndrome. several new emerging bio markers are coming with more sensitivity and specificity.
This document summarizes clinical studies comparing the effects of carvedilol and metoprolol in patients with myocardial infarction (MI) and heart failure (HF). Several studies found that carvedilol improved outcomes more than metoprolol, reducing mortality, improving quality of life, and decreasing hospital readmissions in post-MI and HF patients. Carvedilol's multi-receptor blocking properties allow it to provide better sympatholytic effects than metoprolol. The document concludes that carvedilol is a better choice than metoprolol for treating patients with MI or HF.
CAR T cell basics -cell therapy working group 11.21.19.pptxMuhammad Naeem
This document provides an overview of chimeric antigen receptor T-cell (CART) therapy. It defines CART cells as T-cells modified to express a chimeric antigen receptor (CAR) to target specific antigens on cancer cells. The document describes the process for making CART cells, including collecting T-cells via apheresis, modifying them to express the CAR, expanding the cells in culture, and infusing them into patients. It also discusses FDA-approved CART cell therapies targeting CD19, potential new targets like BCMA, severe toxicities including cytokine release syndrome and neurologic toxicities, and eligibility criteria for CART cell therapy.
The document summarizes a clinical trial that evaluated the angiotensin receptor-neprilysin inhibitor LCZ696 compared to the angiotensin converting enzyme inhibitor enalapril in patients with heart failure with reduced ejection fraction. The trial found that LCZ696 was superior to enalapril in reducing the composite outcome of cardiovascular death or heart failure hospitalization. LCZ696 also reduced rates of all-cause mortality and improved symptoms and physical limitations compared to enalapril. However, LCZ696 was associated with a higher risk of hypotension.
Beta-blockers were developed by Sir James Black in the 20th century and are considered one of the most important medical advances. They are commonly used to treat cardiovascular conditions like hypertension, angina, heart failure, and arrhythmias. Beta-blockers work by blocking beta-adrenergic receptors in the heart and vessels. They have various beneficial effects including reducing heart rate, blood pressure, myocardial oxygen demand, and the risk of arrhythmias. Larger clinical trials demonstrated improved outcomes with beta-blockers in conditions like heart attack and heart failure.
The document discusses monoclonal antibodies, including their discovery, structure, functions, types, production, targets for cancer treatment, and mechanisms of action. It provides details on how monoclonal antibodies can directly kill tumor cells or induce immune-mediated killing through mechanisms like phagocytosis, complement activation, and antibody-dependent cell cytotoxicity. The document also examines immune checkpoint inhibitors, immunotoxins, bispecific antibodies, immunoliposomes, antibody fragments, and an animal model study on monoclonal antibody treatment for colorectal cancer.
Important Clinical Trials In Cardiology - An Overview 2016-17Amit Verma
A randomized clinical trial compared outcomes of 885 patients with STEMI and multivessel disease who underwent primary PCI of an infarct artery and were then randomly assigned to either complete revascularization of additional arteries guided by FFR (fractional flow reserve) or no further intervention. The primary composite outcome of death, MI, revascularization or stroke occurred in 8% of those who received complete revascularization versus 21% of those who received PCI only of the infarct artery. Complete revascularization significantly reduced risk of future cardiovascular events.
This PPT is about immune system and immune therapy, some basic knowledge about Chimeric Antigen Receptor or CAR technology and its application on tumor therapy.
Stem Cells in A New Era of Cell based Therapies - Creative BiolabsCreative-Biolabs
This document discusses stem cells and their applications in cell-based therapies. It defines stem cells as having endless self-renewal and the ability to differentiate into any cell type. Stem cells are classified by potency and origin, and can be embryonic, adult, or induced. The document outlines how different stem cell types like mesenchymal stem cells can treat diseases by regenerating tissues. Current stem cell therapy research aims to treat cancer, autoimmune diseases, and genetic disorders by using stem cells as drug delivery vehicles or for immunotherapy.
cardiac bio markers are important diagnostic and prognostic tool in acute coronary syndrome. several new emerging bio markers are coming with more sensitivity and specificity.
This document summarizes clinical studies comparing the effects of carvedilol and metoprolol in patients with myocardial infarction (MI) and heart failure (HF). Several studies found that carvedilol improved outcomes more than metoprolol, reducing mortality, improving quality of life, and decreasing hospital readmissions in post-MI and HF patients. Carvedilol's multi-receptor blocking properties allow it to provide better sympatholytic effects than metoprolol. The document concludes that carvedilol is a better choice than metoprolol for treating patients with MI or HF.
CAR T cell basics -cell therapy working group 11.21.19.pptxMuhammad Naeem
This document provides an overview of chimeric antigen receptor T-cell (CART) therapy. It defines CART cells as T-cells modified to express a chimeric antigen receptor (CAR) to target specific antigens on cancer cells. The document describes the process for making CART cells, including collecting T-cells via apheresis, modifying them to express the CAR, expanding the cells in culture, and infusing them into patients. It also discusses FDA-approved CART cell therapies targeting CD19, potential new targets like BCMA, severe toxicities including cytokine release syndrome and neurologic toxicities, and eligibility criteria for CART cell therapy.
The document summarizes a clinical trial that evaluated the angiotensin receptor-neprilysin inhibitor LCZ696 compared to the angiotensin converting enzyme inhibitor enalapril in patients with heart failure with reduced ejection fraction. The trial found that LCZ696 was superior to enalapril in reducing the composite outcome of cardiovascular death or heart failure hospitalization. LCZ696 also reduced rates of all-cause mortality and improved symptoms and physical limitations compared to enalapril. However, LCZ696 was associated with a higher risk of hypotension.
Beta-blockers were developed by Sir James Black in the 20th century and are considered one of the most important medical advances. They are commonly used to treat cardiovascular conditions like hypertension, angina, heart failure, and arrhythmias. Beta-blockers work by blocking beta-adrenergic receptors in the heart and vessels. They have various beneficial effects including reducing heart rate, blood pressure, myocardial oxygen demand, and the risk of arrhythmias. Larger clinical trials demonstrated improved outcomes with beta-blockers in conditions like heart attack and heart failure.
The document discusses monoclonal antibodies, including their discovery, structure, functions, types, production, targets for cancer treatment, and mechanisms of action. It provides details on how monoclonal antibodies can directly kill tumor cells or induce immune-mediated killing through mechanisms like phagocytosis, complement activation, and antibody-dependent cell cytotoxicity. The document also examines immune checkpoint inhibitors, immunotoxins, bispecific antibodies, immunoliposomes, antibody fragments, and an animal model study on monoclonal antibody treatment for colorectal cancer.
This document appears to be in Chinese and discusses a herbal medicine practitioner named Zhou Sunhong. However, as the document is in Chinese I do not have enough contextual information to provide a meaningful 3 sentence summary.